Equities

Celon Pharma SA

Celon Pharma SA

Actions
  • Price (EUR)6.22
  • Today's Change0.000 / 0.00%
  • Shares traded50.00
  • 1 Year change+76.20%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 07:13 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of PLN
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments115165228
Total Receivables, Net483427
Total Inventory263823
Prepaid expenses------
Other current assets, total0.560.870.53
Total current assets190238279
Property, plant & equipment, net334342329
Goodwill, net------
Intangibles, net152229
Long term investments111338
Note receivable - long term------
Other long term assets0.320.38--
Total assets569643707
LIABILITIES
Accounts payable111813
Accrued expenses386258
Notes payable/short-term debt000
Current portion long-term debt/capital leases20196.56
Other current liabilities, total17168.99
Total current liabilities8611686
Total long term debt5.717.398.35
Total debt262715
Deferred income tax3.011.326.04
Minority interest------
Other liabilities, total293852
Total liabilities124163153
SHAREHOLDERS EQUITY
Common stock5.115.105.10
Additional paid-in capital------
Retained earnings (accumulated deficit)435467522
Treasury stock - common------
Unrealized gain (loss)4.185.6126
Other equity, total1.681.621.31
Total equity446480554
Total liabilities & shareholders' equity569643707
Total common shares outstanding515151
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.